Thyroid-stimulating hormone (TSH)-secreting pituitary adenomas (TSHomas) represent a rare subset of functional tumors that result in secondary hyperthyroidism. Determining the mechanical consistency of these lesions before an operation remains a significant challenge for neurosurgeons. MR elastography pituitary adenoma characterization has emerged as a promising non-invasive technique to fill this diagnostic gap. Recently, a case involving a 16-year-old female with a giant TSHoma illustrated how this imaging modality provides critical insights into tumor texture before the first incision is made.

Enhancing Precision via MR elastography pituitary adenoma Mapping

During the preoperative phase, a neuroradiologist utilized MR elastography to evaluate the tumor's stiffness. The imaging predicted a soft consistency, which researchers later confirmed during the endoscopic transnasal transsphenoidal excision. Notably, the in vitro shear storage and loss moduli obtained through nanoindentation matched the in vivo findings almost perfectly. Consequently, this alignment underscores the reliability of MRE as a tool for anticipating the technical complexity of pituitary resections.

Furthermore, the investigation revealed that the tumor possessed a collagen content of up to 20% in specific intratumoral regions. Interestingly, the distribution of these structural proteins directly influences the viscoelastic properties measured by MRE. Therefore, the technology does more than just assess firmness; it reflects the underlying histological architecture. Specifically, knowing whether a tumor is soft or fibrous allows the surgical team to prepare specialized equipment, such as ultrasonic aspirators, if a harder consistency is expected.

Clinical Value in Complex Cases

For rare and challenging cases like giant TSHomas, preoperative knowledge of tumor consistency significantly reduces operative uncertainty. If a tumor is identified as soft through MRE, surgeons can proceed with greater confidence using standard suction techniques. Conversely, identifying a firm tumor beforehand allows for a more tailored approach to avoid complications near vital neurovascular structures. Ultimately, integrating advanced imaging into the workflow improves clinical outcomes and simplifies the management of uncommon pituitary pathologies.

FAQs

How does MR elastography help in pituitary surgery?

MR elastography (MRE) provides a non-invasive map of tissue stiffness. By identifying whether a tumor is soft or firm before surgery, neurosurgeons can better plan their approach and select the most effective surgical instruments for tumor removal.

Is tumor consistency related to collagen content?

Yes, higher collagen content is typically associated with increased tumor firmness or fibrosis. MRE can detect these biomechanical changes, providing a window into the tumor's histopathological makeup before an excision is performed.

Why is consistency mapping important for TSHomas?

TSHomas are rare and often present as large or invasive macroadenomas. Knowing the consistency helps in predicting how easily the tumor can be separated from the surrounding gland and critical structures, thereby reducing the risk of surgical morbidity.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Gautam U et al. Biomechanical characterization of thyroid-stimulating hormone-secreting pituitary adenoma using in vivo MR elastography and in vitro nanoindentation: illustrative case. J Neurosurg Case Lessons. 2026 May 25. doi: undefined. PMID: 42184454.

Ball MK, Ehman RL, Huston J 3rd, et al. Predicting pituitary adenoma consistency with preoperative magnetic resonance elastography. J Neurosurg. 2021 Oct 29;136(5):1356-1363. doi: 10.3171/2021.5.JNS21557.

Beck-Peccoz P, Lania A, Beckers A, et al. 2013 European Thyroid Association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J. 2013;2(2):76-82. doi: 10.1159/000351007.